Trace Sensing Technologies
- Company typePrivate
- Founded2020
- HeadquartersWallingford, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Trace Sensing Technologies firmographics
Firmographics- Name
- Trace Sensing Technologies
- Legal name
- Trace Sensing Technologies Inc.
- Website
- https://tracesensingtechnologies.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Trace Sensing Technologies industry classification
Industry- Product category
- Medical Diagnostics Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
- akta.pro secondary industries
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)
Keywords
Where Trace Sensing Technologies is headquartered
LocationHeadquarters
- HQ city
- Wallingford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Trace Sensing Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Medical Diagnostics: Revenue generation through sale of breath-based diagnostic tests and potentially associated hardware/software for CKD screening and early detection in healthcare settings.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Trace Sensing Technologies product offering
Product offeringCore offering
Trace Sensing Technologies develops and sells TRACE-E™, a non-invasive breath-based diagnostic device that detects volatile organic compound (VOC) biomarkers in exhaled breath to enable early-stage diagnosis of chronic kidney disease (CKD). The platform is positioned as a more sensitive, rapid, and patient-friendly alternative to incumbent blood and urine-based diagnostic methods, and is sold to healthcare providers such as nephrologists, primary care physicians, hospitals, and clinics.
Product overview
Trace Sensing Technologies offers a single unified product, TRACE-E, a breath-based diagnostic device designed for early-stage disease detection. The company's primary focus is on Chronic Kidney Disease (CKD), affecting 850 million people worldwide. TRACE-E provides non-invasive, rapid, and sensitive diagnostics that enable earlier intervention compared to traditional methods, with key differentiators in sensitivity, efficiency, durability, and accuracy.
Differentiator
Problem solved
Functional benefit
Brands
- TRACE-E™: A breath-based diagnostic device for early disease detection, focusing on chronic kidney disease (CKD) diagnostics. Features non-invasive testing, rapid results, and superior sensitivity compared to current diagnostic methods.
Products and services
- TRACE-E™ TRACE-E is a breath-based diagnostic device that enables early-stage disease detection through non-invasive testing. It uses exhaled breath analysis to detect VOC biomarkers, providing rapid, accurate, and patient-centric diagnostic results for healthcare providers managing chronic kidney disease, with the goal of eliminating the discomfort, inconvenience, and imprecision of current blood- and urine-based methods.
Quantifiable outcome
- 850 million people worldwide have chronic kidney disease
- +2 more outcomes
Companies that use Trace Sensing Technologies
Customer profileSegments1 record
Ideal customer profiles1 record
Trace Sensing Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Trace Sensing Technologies partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights4 records
Trace Sensing Technologies competitors and assessment
Company assessmentDirect peers
- Menssana Research: Developer of breath-based diagnostic tests (e.g., for lung cancer and pulmonary disease) using VOC profiling. Operates in the same breath-diagnostic category as Trace Sensing with a similar point-of-care testing thesis.
- Healthy.io: Company offering at-home smartphone-based diagnostics, including a FDA-cleared kidney disease urine ACR test. Comparable because it pursues patient-centric, non-lab, point-of-care kidney disease screening and monitoring.
- Renalytix AI: Commercial-stage diagnostics company focused on kidney disease (KidneyIntelX) using blood-based biomarkers and AI for early CKD risk assessment. Comparable as a kidney-disease-specific diagnostics company pursuing earlier, more accurate detection than standard eGFR.
- Owlstone Medical: Pioneer in breath biopsy diagnostics for cancer, inflammatory, and infectious disease using VOC analysis. Most directly comparable to Trace Sensing because both build proprietary breath-based biomarker detection platforms aimed at non-invasive disease diagnosis in clinical settings.
Emerging players
- Caire Diagnostics: Early-stage breath-based diagnostics developer using VOC analysis for lung cancer detection. Comparable as an emerging peer building proprietary breath diagnostics hardware and assay pipelines that overlap with Trace Sensing's technology category.
- Avisa Biochem: Clinical-stage company developing a breath-based test (AVISE UTB) for detecting active pulmonary tuberculosis via VOC biomarkers. Directly comparable breath-diagnostic approach targeting a specific disease state with POC deployment.
- Profusa: Developer of injectable biosensor technology for continuous monitoring of biomarkers (oxygen, glucose, lactate). Comparable as a novel continuous/invasive-minimizing diagnostics platform pursuing multi-indication monitoring, adjacent to Trace Sensing's non-invasive diagnostic thesis.
Broad incumbents
- Quest Diagnostics: Large reference laboratory running the bulk of U.S. eGFR and ACR tests for CKD diagnosis and monitoring. Comparable as the entrenched channel/customer-adjacent incumbent whose reimbursement, ordering, and lab infrastructure shape adoption economics for any novel CKD test.
- BioIntellisense: Remote patient monitoring company offering continuous multi-parameter wearable sensors and a data platform. Comparable as a broader diagnostic/monitoring incumbent pursuing non-invasive, longitudinal health data with enterprise healthcare distribution similar to Trace Sensing's target channels.
- Siemens Healthineers (Renal Diagnostics / eGFR): Major diagnostics incumbent whose clinical laboratory analyzers underpin the standard-of-care serum creatinine/eGFR workflow. Comparable as the entrenched standard-of-care against which any new CKD diagnostic, including TRACE-E, must compete on cost, throughput, and accuracy.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Trace Sensing Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Trace Sensing Technologies leadership team
Management profileNumber of profiles
Trace Sensing Technologies funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Trace Sensing Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Trace Sensing Technologies
What does Trace Sensing Technologies do?
Trace Sensing Technologies develops and sells TRACE-E™, a non-invasive breath-based diagnostic device that detects volatile organic compound (VOC) biomarkers in exhaled breath to enable early-stage diagnosis of chronic kidney disease (CKD). The platform is positioned as a more sensitive, rapid, and patient-friendly alternative to incumbent blood and urine-based diagnostic methods, and is sold to healthcare providers such as nephrologists, primary care physicians, hospitals, and clinics.
Is Trace Sensing Technologies a public or private company?
Trace Sensing Technologies is a private company. It is classified as unknown and is currently operating.
When was Trace Sensing Technologies founded?
Trace Sensing Technologies was founded in 2020. It employs 1 to 10 people.
Where is Trace Sensing Technologies based?
Trace Sensing Technologies is headquartered in Wallingford, United States, in the North America region.
How does Trace Sensing Technologies make money?
One revenue line is on record: medical Diagnostics.
Who are Trace Sensing Technologies's main competitors?
Direct peers on record are Menssana Research, Healthy.io, Renalytix AI and Owlstone Medical. Emerging players are Caire Diagnostics, Avisa Biochem and Profusa. Broad incumbents are Quest Diagnostics, BioIntellisense and Siemens Healthineers (Renal Diagnostics / eGFR).
Does Trace Sensing Technologies have an API?
No public API is recorded for Trace Sensing Technologies.
What industry is Trace Sensing Technologies in?
Trace Sensing Technologies's product category is Medical Diagnostics Devices. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 339112 and its SIC code is 3841.